cancer

FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes
FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes
Bloomberg
FDA
gene therapy
tumor-agnostic therapies
cancer
Scott Gottlieb
Flag link:
Cancer's Big Infrastructure Problem
Cancer's Big Infrastructure Problem
Forbes
cancer
oncology
personalized medicine
clinical trials
clinical trial data
Flag link:
Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment
Novartis’s Next Challenge: Pricing Breakthrough Cancer Treatment
Bloomberg
Novartis
drug pricing
CTL019
cancer
CAR-T
Flag link:
[video]Bristol-Myers Squibb CEO: Critical that treatments reach patients
[video]Bristol-Myers Squibb CEO: Critical that treatments reach patients
Yahoo/CNBC
patients
cancer
Bristol-Myers Squibb
drug pricing
ASCO 2017
Giovanni Caforio
Flag link:
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
Forbes
cancer
oncology
larotrectinib
Loxo Oncology
clinical trials
patients
Flag link:
New report heralds a revolution in cancer R&D trends – and the sticker shock that comes with it
New report heralds a revolution in cancer R&D trends – and the sticker shock that comes with it
Endpoints
cancer
R&D
drug development
Flag link:
Novartis sees gaps in cancer pipeline but is adamant it doesn’t need an I-O deal
Novartis sees gaps in cancer pipeline but is adamant it doesn’t need an I-O deal
Fierce Biotech
Novartis
cancer
immuno-oncology
Flag link:
On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy
On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy
Xconomy
ASCO 2017
cancer
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Flag link:
Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker
Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker
Endpoints
Merck
Keytruda
FDA
biomarkers
cancer
Flag link:
Teva says it's eyeing a debt-cutting sale of its cancer meds
Teva says it's eyeing a debt-cutting sale of its cancer meds
Fierce Pharma
Teva Pharmaceutical
M&A
cancer
Flag link:
Bristol-Myers preps second checkpoint/cancer vax combo study under its $1B Bavarian Nordic pact
Bristol-Myers preps second checkpoint/cancer vax combo study under its $1B Bavarian Nordic pact
Endpoints
Bristol-Myers Squibb
cancer
vaccines
Bavarian Nordic
Prostvac
Opdivo
Yervoy
Flag link:
Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO
Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO
Endpoints
G1 Therapeutics
IPOs
Pfizer
Novartis
Eli Lilly
cancer
R&D
Flag link:
The cost of cancer: new drugs show success at a steep price
The cost of cancer: new drugs show success at a steep price
Yahoo/Reuters
cancer
Bristol-Myers Squibb
Merck
Roche
Flag link:
How AbbVie Is Attacking Tumors at Their Roots
How AbbVie Is Attacking Tumors at Their Roots
Motley Fool
AbbVie
solid tumors
cancer
stem cells
Stemcentrx
Rova-T
Flag link:
Cancer patients skipping medicines or delaying treatment due to high drug prices
Cancer patients skipping medicines or delaying treatment due to high drug prices
Stat
patients
oncology
cancer
drug pricing
Flag link:
Billionaire-backed Chi-Med declares PhIII success for pioneering cancer drug in China, seeking quick OK
Billionaire-backed Chi-Med declares PhIII success for pioneering cancer drug in China, seeking quick OK
Endpoints
Chi-Med
fruquintinib
oncology
cancer
China
Flag link:
MD Anderson Benches IBM Watson In Setback For Artificial Intelligence In Medicine
MD Anderson Benches IBM Watson In Setback For Artificial Intelligence In Medicine
Forbes
IBM
artificial intelligence
cancer
Watson
MD Anderson Cancer Center
Flag link:
5 trends being impacted by biomarkers
5 trends being impacted by biomarkers
BioPharma Dive
biomarkers
precision medicine
combo trials
diagnostics
R&D
cancer
liquid biopsy
Flag link:
Most new, high-priced cancer drugs don’t even extend life for 10 weeks
Most new, high-priced cancer drugs don’t even extend life for 10 weeks
ARS Technica, UK
cancer
oncology
Flag link:
Amgen, Immatics In Cancer Drug Partnership
Amgen, Immatics In Cancer Drug Partnership
Investopedia
Amgen
Immatics
bispecific antibodies
R&D
cancer
Flag link: